299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01181622 (ClinicalTrials.gov)	August 2010	12/8/2010	A Safety and Tolerability Study of Denufosol in 2-4 Year Olds	A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC® Star in Patients 2 to 4 Years of Age With Cystic Fibrosis	Cystic Fibrosis	Drug: denufosol tetrasodium Inhalation Solution;Drug: 0.9% w/v sodium chloride solution	Merck Sharp & Dohme Corp.	NULL	Completed	2 Years	4 Years	Both	25	Phase 2	United States
2	NCT00846781 (ClinicalTrials.gov)	February 2009	18/2/2009	Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)		Cystic Fibrosis	Drug: Denufosol tetrasodium Inhalation Solution	Merck Sharp & Dohme Corp.	NULL	Terminated	5 Years	N/A	Both	308	Phase 3	United States;Australia;Canada;New Zealand
3	NCT00625612 (ClinicalTrials.gov)	February 2008	12/2/2008	Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease	A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease and FEV1 Greater Than or Equal to 75% Predicted But Less Than or Equal to 110% Predicted	Cystic Fibrosis	Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution;Drug: Placebo	Merck Sharp & Dohme Corp.	NULL	Completed	5 Years	N/A	Both	466	Phase 3	United States;Australia;Canada;New Zealand